111 Capital Acquires New Holdings in Zoetis Inc. $ZTS

Key Points

• 111 Capital has acquired a new stake in Zoetis Inc. (NYSE: ZTS), purchasing 26,014 shares valued at approximately $4,057,000, making it the fund's 23rd largest position.
• Several institutional investors, including Vanguard Group and Goldman Sachs, have increased their holdings in Zoetis, with institutional ownership now at 92.80% of the company's stock.
• Zoetis recently reported earnings of $1.76 per share, exceeding expectations, and has set a FY 2025 guidance of 6.300-6.400 EPS, with analysts expecting a current year EPS of 6.07.

111 Capital purchased a new stake in Zoetis Inc. (NYSE:ZTS - Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 26,014 shares of the company's stock, valued at approximately $4,057,000. Zoetis makes up about 0.7% of 111 Capital's holdings, making the stock its 23rd biggest position.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Vanguard Group Inc. boosted its holdings in shares of Zoetis by 0.5% in the first quarter. Vanguard Group Inc. now owns 41,556,164 shares of the company's stock valued at $6,842,222,000 after buying an additional 189,287 shares during the period. Polen Capital Management LLC boosted its holdings in shares of Zoetis by 17.6% in the first quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company's stock valued at $1,448,401,000 after buying an additional 1,313,653 shares during the period. Northern Trust Corp boosted its holdings in shares of Zoetis by 1.2% in the first quarter. Northern Trust Corp now owns 6,504,902 shares of the company's stock valued at $1,071,032,000 after buying an additional 78,508 shares during the period. Goldman Sachs Group Inc. boosted its holdings in shares of Zoetis by 2.2% in the first quarter. Goldman Sachs Group Inc. now owns 5,146,024 shares of the company's stock valued at $847,293,000 after buying an additional 109,791 shares during the period. Finally, Brown Advisory Inc. boosted its holdings in shares of Zoetis by 7.6% in the first quarter. Brown Advisory Inc. now owns 4,408,542 shares of the company's stock valued at $725,866,000 after buying an additional 312,746 shares during the period. Institutional investors and hedge funds own 92.80% of the company's stock.

Zoetis Stock Performance

NYSE ZTS opened at $146.45 on Friday. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05. The firm's fifty day moving average price is $149.79 and its two-hundred day moving average price is $155.14. Zoetis Inc. has a 1 year low of $139.34 and a 1 year high of $196.55. The firm has a market capitalization of $64.91 billion, a P/E ratio of 25.21, a price-to-earnings-growth ratio of 2.35 and a beta of 0.90.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.62 by $0.14. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The firm had revenue of $2.46 billion for the quarter, compared to analyst estimates of $2.41 billion. During the same period in the prior year, the firm posted $1.56 earnings per share. The company's quarterly revenue was up 4.2% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, research analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current year.

Wall Street Analysts Forecast Growth

ZTS has been the subject of several research analyst reports. Leerink Partners cut shares of Zoetis from an "outperform" rating to a "market perform" rating and reduced their price target for the company from $180.00 to $155.00 in a report on Thursday, July 17th. Stifel Nicolaus lowered shares of Zoetis from a "buy" rating to a "hold" rating and cut their price objective for the stock from $165.00 to $160.00 in a research report on Wednesday, June 18th. Leerink Partnrs lowered shares of Zoetis from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 17th. Argus reissued a "buy" rating and issued a $190.00 price objective on shares of Zoetis in a research report on Tuesday, September 9th. Finally, Piper Sandler boosted their price objective on shares of Zoetis from $210.00 to $215.00 and gave the stock an "overweight" rating in a research report on Monday, August 11th. Five analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $200.88.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.